Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479621 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 909
- Enrollment target
NCT01479621: Completed Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT01479621 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 909 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (583% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01479621, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 909 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate delivered as Fluticasone Propionate DPI (Dry Powder Inhaler) when administered twice daily.
Primary Outcome
Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + s
Interventions
- DRUG Placebo MDPI
- DRUG Fp MDPI
- DRUG albuterol/salbutamol
- DRUG Flovent Diskus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 909 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
What the finished NCT01479621 record still lists
NCT01479621 is an interventional study that assigns participants to a tested intervention. The registered 909 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (583% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo MDPI is the first listed.
NCT01479621 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01479621 about?
NCT01479621 is a clinical study titled "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids". This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate t...
What is the current status of trial NCT01479621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 909 participants. The study started on 2012-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01479621?
The interventions under investigation include: Placebo MDPI (DRUG), Fp MDPI (DRUG), albuterol/salbutamol (DRUG), Flovent Diskus (DRUG).
Who is sponsoring clinical trial NCT01479621?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01479621's enrollment target sits among peer trials
909 30th of 2000 higher than 1,971 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia